Body Weight and eGFR during Dulaglutide Treatment in Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease (AWARD-7).

Authors

Katherine Tuttle, Providence Health Care, Spokane, WAFollow
Mark C Lakshmanan
Brian Rayner
Alan G Zimmermann
D Bradley Woodward
Fady T Botros

Document Type

Article

Publication Date

2-14-2019

Publication Title

Diabetes, obesity & metabolism

Abstract

In patients with T2D and moderate-to-severe CKD, dulaglutide treatment led to body weight (BW) loss and lesser eGFR decline compared to insulin glargine. Since BW may affect muscle mass, creatinine-based eGFR can be altered independent of kidney function. Cystatin C-based eGFR is not affected by muscle mass. The objective of this post-hoc analysis was to evaluate if lesser eGFR decline with dulaglutide was related to BW loss. Baseline characteristics were similar between treatments ([mean±SD] age: 64.6±8.6 years, women: 48%, BW: 89.1±17.7 kg, eGFR [CKD-EPI-cystatin C] 38±14 mL/min/1.73m

Clinical Institute

Kidney & Diabetes

Department

Nephrology

Department

Endocrinology

Recommended Citation

Tuttle, Katherine; Lakshmanan, Mark C; Rayner, Brian; Zimmermann, Alan G; Woodward, D Bradley; and Botros, Fady T, "Body Weight and eGFR during Dulaglutide Treatment in Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease (AWARD-7)." (2019). Articles, Abstracts, and Reports. 1160.
https://digitalcommons.providence.org/publications/1160